erythrocyte membrane protein band 4.1 like 2Genealiases: 4.1-G · 4.1G
Q-omics provides the consensus-scored EPB41L2 profile across patient tissues and cancer cell-line models. EPB41L2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, EPB41L2 protein abundance shows 27,275 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where EPB41L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L2 survival associations across molecular data types. EPB41L2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L2 RNA expression–survival associations across cancer types. High EPB41L2 expression shows unfavorable associations in OV, LIHC, KICH and LAML, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L2 RNA expression.
This table summarizes EPB41L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for EPB41L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L2 shows lower tumor expression in THCA, LUAD and BLCA and higher tumor expression in KIRC, COAD and KIRP. The KIRC box plot shows higher EPB41L2 RNA expression in tumor versus normal tissue (log2 FC = +0.795, t-test p < 0.001).
This table shows molecular features associated with EPB41L2 in patient tissues and cancer cell lines. In patient samples, EPB41L2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
